Webinar: Dr. E. John Wherry Looks at Cancer Immunotherapy in 2022

Webinar Watch With tremendous focus on immunology during the COVID-19 pandemic, scientific knowledge of our immune system and its application to other diseases has grown. Cancer immunotherapy has made several advances with new drug approvals and combinations in multiple cancers as well as an expanding range of immunotherapy treatment types. In this webinar for patients and caregivers, E. John Wherry, Ph.D., of the University of Pennsylvania, discusses what might lie ahead for the field in 2022—and what it means for patients. New types of immunotherapy entering clinical trials Liquid biopsies and new innovations in biomarker testing Innovative combinations of immunotherapies with other cancer treatments WATCH THE WEBINAR   Dr. E. John Wherry is the Barbara and Richard Schiffrin President’s Distinguished Professor, chair of the Department of Systems Pharmacology and Translational Therapeutics in the Perelman School of Medicine and director of the UPenn Institute for Immunology. Dr. Wherry’s expertise lies mainly in T cell exhaustion, which can hamper anti-tumor immune responses. He has published over 200 papers, many of which have helped advance our understanding of how gene expression changes affect this exhaustion, which has led to strategies to improve the effectiveness of T cell-targeting immunotherapies. He is an associate director of the CRI Scientific Advisory Council.   Cancer Immunotherapy and You Webinars™ are produced by the Cancer Research Institute and hosted by our assistant director of scientific content, Arthur N. Brodsky, Ph.D. The 2022 series is made possible with generous support from Bristol Myers Squibb and Lilly Oncology. The webinar series is part of the Cancer Research Institute Answer to Cancer Patient Education Program. Browse our webinar playlist on YouTube or visit the webinars page on our website to see other installments in this series.